Donald C. Moore

Nov 3, 2024 | onlinelibrary.wiley.com | Hanny Al-Samkari |Donald C. Moore

In their paper, Galamaga and colleagues present a case series of six patients with persistent chemotherapy-induced thrombocytopenia (CIT) who were successfully treated with the oral thrombopoietin receptor agonist (TPO-RA) avatrombopag.1 All six patients appeared to benefit from avatrombopag support, with robust improvements in platelet counts facilitating continued chemotherapy with minimal chemotherapy dose reductions and/or treatment delays.